FDA Draft Guidance Extends Reprint Policy To Medical Reference Texts, Clinical Practice Guidelines
This article was originally published in The Gray Sheet
Executive Summary
FDA has revised, but not loosened, its 2009 policy on the practices manufacturers should follow when giving physicians reprints of journal articles and other publications that discuss unapproved uses of legally marketed medical devices and drugs.
You may also be interested in...
Off-Label Questions, Online: FDA Explains How To Handle Them
FDA draft guidance weighs in on web communications, saying that firms must answer off-label-information questions privately, even if the questions arise in a public online forum.
FDA Issues Guidance On Off-Label Info; Waxman Seeks ‘Re-examination’
Rep. Henry Waxman is calling for the Obama administration to re-examine a final FDA guidance that gives companies a way to distribute journal articles discussing off-label uses for approved medical devices and drugs
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.